Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference

Epilepsy Research

Volumn 25, Issue 3, 1996, Pages 299-319

  Bialer, M ^a   Johannessen, S I ^b   Kupferberg, H J ^c   Levy, R H ^d   Loiseau, P ^e   Perucca, E ^f  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b National Center for Epilepsy   (Norway)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HÔPITAL PELLEGRIN   (France)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

antiepileptic drug development; clinical trial design; drug approval

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; DEZINAMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; NEW DRUG; OXCARBAZEPINE; RALITOLINE; REMACEMIDE; RETIGABINE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALROCEMIDE; VIGABATRIN;

APLASTIC ANEMIA; ATAXIA; CONFERENCE PAPER; DIPLOPIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; EPILEPSY; FATIGUE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NYSTAGMUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; AZETIDINES; CARBAMATES; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; ISRAEL; NIPECOTIC ACIDS; PHENYLENEDIAMINES; PIRACETAM; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; THIAZOLES; TRIAZOLES;

EID: 0030297333     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(96)00081-2     Document Type: Conference Paper

References (40)

1. [1] Banfield, C.R. and Levy, R.H., Felbamate: Interaction with other drugs. In: R.H. Levy, R.H. Mattson and B.S. Meldrum (Eds.), Antiepileptic Drugs, 4th Edn., Raven Press, New York, 1995, pp. 813-816.
2. [2] Ben-Menachem, E., Topiramate. In: R.H. Levy, R.H. Mattson and B.S. Meldrum (Eds). Antiepileptic Drugs, 4th Edn., Raven Press, New York, 1995, pp. 1063-1070.
3. [3] Brodie, M.J., Richens, A. and Yuen, A.W.C., For the UK lamotrigine/ carbamazepine monomerapy trial group, double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy, Lancet, 345 (1995) 476-479.
4. [4] Buchanan, N., Clobazam in the treatment of epilepsy: Prospective follow-up to 8 years, J. R. Soc. Med., 86 (1993) 378-380.
5. [5] Cheung, W.K., Kianifard, F., Wong, A., Mathieu, J., Cook, T., John, V., Redalieu, E. and Chan, K., Intra-and inter-subject variabilities of CGP 33 101 after replicate single oral doses of two 200 mg tablets and 400 mg suspension, Pharm. Res., 12 (1995) 1878-1882.
6. [6] Christe, W., Krämer, G., Vigonius, U., et al., A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy, Epilepsy Res., in press.
7. [7] Clark, B., Hutchison, J.B., Jamieson, V., Jones, T., Palmer, E.C. and Scheyer, R.D., Remacemide hydrochloride. In: R.H. Levy, R.H. Mattson and B.S. Meldrum (Eds.), Antiepileptic Drugs, 4th Edn., Raven Press, New York, 1995, pp. 1035-1044.
8. [8] Cloyd, J., Pharmacologic considerations of fosphenytoin therapy, Pharm. Ther., 21 (Suppl.) (1996) 13s-20s.
9. [9] Dam, M., Ekberg, R., Løyning, Y., et al., A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy, Epilepsy Res., 3 (1989) 70-76.
10. [10] DeToledo, J. and Ramsay, R.E., IM administration of fosphenytoin, Emerg. Med. Clin. North Am., 28(4) (Suppl.) (1996) 26-32.
11. [11] Garofalo, E.A., Hayes, A.G., Greeley, C.A., Hes, M.S., et al., An open-label extension study of gabapentin monotherapy in patients with medically refractory partial seizures, Epilepsia, 36 (Suppl. 4) (1995) 68.
12. [12] Gower, A.J., Noyer, M., Verloes, R., Gobert, J. and Wülfert, E., ucb LO59, a novel anti-convulsant drug: Pharmacological profile in animals, Eur. J. Pharmacol., 222 (1992) 193-202.
13. [13] Guerreiro, M.M., Vigonius, U., Pohlmann, H., et al., A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adults with epilepsy, Acta. Neural. Scand., in press.
14. [14] Hadad, S. and Bialer, M., Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine, Pharm. Res., 12 (1995) 905-910.
15. [15] Hes, M.S., Trudeau, V.L., Kilgore, M.B., Poulter, C.J., et al., A double-blind, placebo-controlled, randomized multicenter trial of gabapentin in pediatric patiens with Benign Childhood Epilepsy with Centrotemporal Spikes (BECTS), Epilepsia, 36 (Suppl. 4) (1995) 125.
16. [16] Jensen, P.K., Felbamate in the treatment of refractory partial-onset seizures, Epilepsia, 34 (Suppl. 7) (1993) S25-S29.
17. [17] Jensen, P.K., Felbamate in the treatment of Lennox-Gastaut syndrome, Epilepsia, 35 (Suppl. 5) (1994) S54-S57.
18. [18] Kalviainen, R., Aikia, M., Saukkonen, A.M., Mervaala, E. and Riekkinen Sr., P.J., Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy, Arch. Neurol., 52 (1995) 989-996.
19. [19] Knapp, L.E., Kugler, A.R. and Eldon, M.A., Fosphenytoin: Pharmacokinetics and administration, Emerg. Med. Clin. North Am., 28 (Suppl.) (1996) 9-16.
20. [20] Leppik, I.E. and Gram, L., Tiagabine: The art of epilepsy care, Epilepsia, 36 (Suppl. 6) (1995) S1-S26.
21. [21] Levinson, D.F., Vigabatrin and psychosis, Epilepsia, 4 (Suppl. 4) (1995) 32.
22. [22] Löscher, W., von Hodenberg, A., Nolting, B., Fassbender, C.-P. and Taylor, C., Ralitoline: A reevaluation of anticonvulsant profile and determination of 'active' plasma concentrations in comparison with prototype antiepileptic drugs in mice, Epilepsia, 32 (1991) 560-568.
23. [23] Messenheimer, J.A., Lamotrigine, Epilepsia, 36 (Suppl. 2) (1995) S87-S94.
24. [24] Noyer, M., Gillard, M., Matagne, A., Hendhart, J.P. and Walfert, E., The novel antiepileptic drug levetiracetam (ucb LO59) appears to act via a specific binding site in CNS membranes, Eur. J. Pharmacol., 286 (1995) 136-147.
25. [25] Palmer, G.C., Clark, B. and Hutchison, J.B., Antiepileptic and neuroprotective potential of remacemide hydrochloride, Drugs of the Future, 18 (1993) 1021-1042.
26. [26] Petroff, A.C.O., Rothman, D.L., Behar, K.L. and Mattson, R.H., Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose, Neurology, 46 (1996) 1459-1463.
27. [27] Pledger, G.W., Laxer, K.D., Sahlroot, J.T., Taylor, M.R., Cereghino, J.J., McCormick, C., Whitley, L. and Manning, L.W., Pharmacokinetic and dose tolerability study of ADD 94057 in comedicated patients with partial seizures, Epilepsia, 33 (1992) 114-118.
28. [28] Privitera, M.D., Treiman, D.M., Pledger, G.W., Sahlroot, J.T., Handforth, A., Linde, M.S., France, C.R., Cereghino, J.J., McCutchen, C.B. and Wood, J.H., Dezinamide for partial seizures: Results of an n-of-1 design trial, Neurology, 44 (1994) 1453-1458.
29. [29] Reife, R.A., Topiramate - A novel anti-epileptic drug. In: S. Shorvon, D. Fish, F. Dreifuss and D. Thomas (Eds.), The Treatment of Epilepsy, 1995, pp. 471-481.
30. [30] Rostock, A., Tober, C., Rundfeldt, C., Bartschm R., Engel, J., Poymeropoulos, E., Kutscher, B., Löscher, W., Hönack, D., White, H.S. and Wolf, H.H., D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res., 23 (1996) 211-213.
31. [31] Rothstein, J.D. and Kuncl, R.W., Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity, J. Neurochem, 65 (1995) 643-651.
32. [32] Rowan, J.A., Uthman, B., Ahmann, P., Wannamaker, B.B., Schachter, S.C., Shu, V., Chang, S., Curry, T., Hightower, B. and Sommerville, K.W., Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures, Epilepsia, 35 (Suppl. 8) (1994) 54.
33. [33] Sachdes, R., Leroy, R., Krauss, G., Green, P., Drake, M., Leppik, I., Shu, V., Ringham, G.L. and Sommerville, K.W., Safety and efficacy of BID and QID dosing with tiagabine HCl versus placebo as adjunctive treatment for partial seizures, Neurology, 45 (Suppl. 4) (1995) A202.
34. [34] Singh, A., Guberman, A.H., Boivert D., Clobazam in long-term epilepsy: Sustained responders versus those developing tolerance, Epilepsia, 36 (1995) 798-803.
35. [35] Stables, J.P., Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P. and Perucca, E., Progress report on new antiepileptic drugs - A summary of the Second Eilat Conference, Epilepsy Res., 22 (1995) 235-246.
36. [36] Su, T.-Z., Lunney, E., Campbell, G. and Oxender, D.L., Transport of gabapentin, a γ-amino acid drug, by system L α-amino acid transporters: A comparative study in astrocytes, synaptosomes and CHO cells, J. Neurochem., 64 (1995) 2125-2131.
37. [37] Tober, C., Rostock, A., Rundfeldt, C. and Bartsch, R., D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures, Eur. J. Pharmacol., 303 (1996) 163-169.
38. [38] Tober, C., Rundfeldt, C., Rostock, A., Bartsch, R., Nickel, B., Szeleny, I., Herbst, M., Dieter, R., Olbrich, A., Kutscher, B., Sauer, W., Jainta, H., Jahn, W. and Engel, J., D-23129, Drugs of the Future, 20 (1995) 1112-1115.
39. [39] Victor, S.J., Dezinamide, In: J. Engel and T.A. Pedley (Eds.), Epilepsy, A Comprehensive Textbook, Raven Press, 1996.
40. [40] Walker, M.C., Sharief, M.K., Sander, J.W.A.S., Patsalos, P.N. and Shorvon, S.D., Early experience with ucb LO59 in refractory epilepsy, Epilepsia, 35 (Suppl. 7) (1994) 76.